| ID Source | ID |
|---|---|
| PubMed CID | 6441236 |
| CHEMBL ID | 151870 |
| SCHEMBL ID | 678719 |
| MeSH ID | M0272543 |
| Synonym |
|---|
| agn 190121 |
| benzoic acid, 4-(4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-1-ynyl)-, (e)- |
| (e)-4-(4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-1-ynyl)benzoic acid |
| CHEMBL151870 , |
| 4-[(e)-4-(2,6,6-trimethyl-cyclohex-1-enyl)-but-3-en-1-ynyl]-benzoic acid |
| bdbm50097824 |
| 4-[(e)-4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-1-ynyl]benzoic acid |
| 132032-67-8 |
| SCHEMBL678719 |
| agn-190121 |
| PD160878 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Retinoic acid receptor alpha | Homo sapiens (human) | EC50 (µMol) | 0.4350 | 0.0002 | 0.1790 | 2.5119 | AID197921 |
| Retinoic acid receptor alpha | Homo sapiens (human) | Kd | 0.1350 | 0.0002 | 0.5268 | 9.5000 | AID198050 |
| Retinoic acid receptor beta | Homo sapiens (human) | EC50 (µMol) | 0.0070 | 0.0003 | 0.2311 | 6.9000 | AID198377 |
| Retinoic acid receptor beta | Homo sapiens (human) | Kd | 0.0200 | 0.0002 | 0.2876 | 2.3000 | AID198539 |
| Retinoic acid receptor gamma | Homo sapiens (human) | EC50 (µMol) | 0.0100 | 0.0002 | 0.0613 | 0.6480 | AID198898 |
| Retinoic acid receptor gamma | Homo sapiens (human) | Kd | 0.1900 | 0.0002 | 0.4245 | 3.8240 | AID199050 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID198539 | Binding affinity towards retinoic acid receptor beta was determined using [3H]ATRA (5 nM) as radioligand | 2001 | Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6 | Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity. |
| AID198898 | Ability to inhibit TTNPB-induced transactivation at retinoic acid receptor gamma | 2001 | Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6 | Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity. |
| AID198377 | Ability to inhibit TTNPB-induced transactivation at retinoic acid receptor beta | 2001 | Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6 | Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity. |
| AID199050 | Binding affinity towards retinoic acid receptor gamma was determined using [3H]ATRA (5 nM) as radioligand | 2001 | Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6 | Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity. |
| AID197921 | Ability to inhibit TTNPB-induced transactivation at retinoic acid receptor alpha | 2001 | Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6 | Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity. |
| AID198050 | Binding affinity towards retinoic acid receptor alpha was determined using [3H]ATRA (5 nM) as radioligand | 2001 | Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6 | Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||